"Targeting cancer drugs to the tumor for improved patient outcomes"
VAST is an innovative small molecule discovery platform with unique 3D compound shapes that expand chemical diversity.
Audeo is a late-stage, oncology focused biopharmaceutical company with an integrated pipeline of products stemming from two core technology platforms
Alchemia has a marketed product and a late stage oncology pipeline.
Audeo Oncology is a wholly owned subsidiary of Alchemia, established to capitalise on HA-Irinotecan.
HyACT is a flexible platform technology that we are using to target cancer drugs directly to tumors. More...
Wants more information about Audeo, our products or investing?
